Gland Pharma posts 16% revenue growth in Q1 FY25

The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore

USFDA inspects Gland Pharma’s Dundigal facility

The inspection was concluded with two 483 observations

Gland Pharma receives USFDA’s tentative approval for Latanoprostene Bunod Ophthalmic Solution

The product is bioequivalent and therapeutically equivalent to the reference listed drug

Gland Pharma receives approval for Edaravone Injection

The product is used to treat amyotrophic lateral sclerosis

Gland Pharma appoints Satnam Singh Loomba as COO

Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.

Gland Pharma receives approval for cetrorelix acetate for injection

Gland Pharma receives USFDA approval for Eribulin Mesylate Injection

The Product is expected to be the first generic approval on the market

Gland Pharma posts Q2 FY24 consolidated PAT at Rs. 194.08 Cr

Gland Pharma has reported total income of Rs. 1426.57 crores during the period ended September 30, 2023

Gland Pharma receives 2 observations under 483 for Pashamylaram facility

The company is committed to address the observations and will submit its response to US FDA within the stipulated time

Gland Pharma posts Q1 FY24 consolidated PAT at Rs. 194.10 Cr

Gland Pharma has reported total income of Rs. 1246.23 crores during the period ended June 30, 2023